---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-26-000063"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2026-08-06T11:23:01+00:00"
generated_at: "2026-08-06T11:25:13.759656+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q2 XDEMVY sales $173.9M (+69% YoY); raises FY guidance to $685-705M; acquires Alkeus

## Summary
- XDEMVY net product sales $173.9M in Q2 2026, up >69% YoY; full-year guidance raised to $685-705M.
- Net loss narrowed to $18.6M ($0.43 loss per share) from $20.3M ($0.48) in Q2 2025.
- Cash, cash equivalents and marketable securities $449.7M as of June 30, 2026.
- Announced agreement to acquire Alkeus Pharmaceuticals (Phase 3 Stargardt disease therapy) and $125M private placement.
- Appointed Neera Clase as Interim Chief Commercial Officer; pipeline milestones on track.

## SEC filing metadata
- accession: 0001819790-26-000063
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2026-08-06T11:23:01+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/0001819790-26-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/tars-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-26-000063
- JSON: https://secwatch.observer/filing/0001819790-26-000063.json
- Plain text: https://secwatch.observer/filing/0001819790-26-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.